Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Di first head-to-head trial of two ogbonge weight-loss drugs show say Mounjaro dey more effective pass im rival Wegovy. Both ...

Trump's order seeks to ease regulations to compel more U.S. drug manufacturing. He also plans to assess tariffs on drug ...

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...

Preview in new tab Pharmaceutical giants Eli Lilly ($LLY) and Novo Nordisk ($NVO) are engaged in a head-to-head battle to ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...